Outside factors
How new hemophilia products could usher in personalized treatment strategies
This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades. These new products could enable a more personalized approach to treating subsets of patients based on disease severity and individual preference.
The most advanced is a mAb in Phase III testing that mimics the biological role of Factor VIII. Four earlier stage programs are focused on rebalancing the coagulation cascade (see “Next Wave in Hemophilia”)...
BCIQ Company Profiles
BCIQ Target Profiles